Scientific Journals for June 2015

American journal of opthalmology

Local recurrence after primary proton beam therapy in uveal melanoma: Risk factors, retreatment approaches and outcome

Ira Seibel, Dino Cordini, Matus Rehak, Annette Hager, Aline I. Riechardt, Alexander Böker, Jens Heufelder, Andreas Weber, Johannes Gollrad, Angela Besserer, Antonia M. Joussen

Received: February 12, 2015; Received in revised form: June 18, 2015; Accepted: June 20, 2015; Published Online: June 29, 2015

Publication stage: In Press Accepted Manuscript

DOI: http://dx.doi.org/10.1016/j.ajo.2015.06.017

_____________________________________________________________________________________________________________________________________________

Journal of Clinical Oncology

Citrus Consumption and Risk of Cutaneous Malignant Melanoma

Published online before print June 29, 2015,
doi:10.1200/JCO.2014.57.4111 JCO
June 29, 2015 JCO.2014.57.4111

____________________________________________________________________________________________________________________________________________

ONCOGENE

Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling

E Flashner-Abramson¹,
S Klein¹,
G Mullin¹,
E Shoshan²,
R Song²,
A Shir¹,
Y Langut¹,
M Bar-Eli²,
H Reuveni^{1,

3,

4,

5}
and A Levitzki^1,

4

Received 5 March 2015; Revised 14 May 2015; Accepted 18 May 2015
Advance online publication 29 June 2015

____________________________________________________________________________________________________________________________________________________

The Lancet

The place of PD-1 inhibitors in melanoma management

Samantha Bowyer Paul Lorigan

Published Online: 23 June 2015

DOI: http://dx.doi.org/10.1016/S1470-2045(15)00094-7

___________________________________________________________________________________________________________________________________________

NATURE REVIEWS CLINICAL ONCOLOGY | NEWS AND VIEWS

Immunotherapy: Combined immunotherapy—a new standard in metastatic melanoma?

Axel Hauschild &Claus Garbe

Nature Reviews Clinical Oncology(2015)

doi:10.1038/nrclinonc.2015.118

Published online 23 June 2015

____________________________________________________________________________________________________________________________________

NATURE REVIEWS CLINICAL ONCOLOGY | RESEARCH HIGHLIGHT | IN BRIEF

MELANOMA

Dabrafenib and trametinib improve overall survival

Nature Reviews Clinical Oncology(2015)

Published online 23 June 2015

doi:10.1038/nrclinonc.2015.114

________________________________________________________________________________________________________________________________

Long, G. V. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Lancet doi:10.1016/S0140-6736(15)60898-4

____________________________________________________________________________________________________________________________

Br J Cancer. 2015 Jun 9;112(12):1904-10. doi: 10.1038/bjc.2015.180. Epub 2015 May 26.

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.

Ferrucci PF¹, Gandini S², Battaglia A¹, Alfieri S¹, Di Giacomo AM³, Giannarelli D⁴, Cappellini GC⁵, De Galitiis F⁵, Marchetti P⁶, Amato G³, Lazzeri A³, Pala L¹, Cocorocchio E¹, Martinoli C¹.

_________________________________________________________________________________________________________________________

CELL

Genomic Classification of Cutaneous Melanoma

The Cancer Genome Atlas Network,

*Correspondence: irwatson@mdanderson.org (I.R.W.), jgershen@mdanderson.org (J.E.G.), lchin@mdanderson.org (L.C.)

http://dx.doi.org/10.1016/j.cell.2015.05.044

_____________________________________________________________________________________________________________________________

NATURE REVIEWS CLINICAL ONCOLOGY | RESEARCH HIGHLIGHT

SKIN CANCER

T-VEC oncolytic viral therapy shows promise in melanoma

David Killock

Nature Reviews Clinical Oncology (2015)

doi:10.1038/nrclinonc.2015.106

Published online 16 June 2015

_____________________________________________________________________________________________________________________________

The Lancet

Combination immunotherapy breakthrough for melanoma

Vicki Brower

Published Online: 07 June 2015

DOI: http://dx.doi.org/10.1016/S1470-2045(15)00030-3

____________________________________________________________________________________________________________________________

The BMJ

US melanoma prevalence has doubled over past 30 years

2015; 350 doi: http://dx.doi.org/10.1136/bmj.h3074 (Published 04 June 2015)Cite this as: 2015;350:h3074

Michael McCarthy

____________________________________________________________________________________________________________________________

The BMJ

Combined immunotherapy improves survival in metastatic melanoma

2015; 350 doi: http://dx.doi.org/10.1136/bmj.h2993 (Published 02 June 2015)Cite this as: 2015;350:h2993

Susan Mayor

________________________________________________________________________________________________________________________________

The Lancet

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V Long, MD,
Daniil Stroyakovskiy, MD,
Helen Gogas, MD,
EvgenyLevchenko, MD,
Filippo de Braud, MD,
James Larkin, FRCP,
Prof Claus Garbe, MD,
Thomas Jouary, MD,
Prof Axel Hauschild, MD
Prof Jean-Jacques Grob, MD
Vanna Chiarion-Sileni, MD
Prof Celeste Lebbe, MD
Mario Mandalà, MD
Prof Michael Millward, MD
Ana Arance, MD
ProfIgor Bondarenko, MD
Prof John B A G Haanen, MD
Prof Johan Hansson, MD
Prof Jochen Utikal, MD
Virginia Ferraresi, MD
Prof Nadezhda Kovalenko, MD
Peter Mohr, MD
Volodymr Probachai, MD
Prof Dirk Schadendorf, MD
Paul Nathan, MD
Caroline Robert, MD
Prof Antoni Ribas, MD
Douglas J DeMarini, PhD^†Jhangir G Irani, MA^†Suzanne Swann, PhD^†Jeffrey J Legos, PhD^†Fan Jin, MD^†Bijoyesh Mookerjee, MD^†Keith Flaherty, MD

^{†Employees of GlaxoSmithKline during the study}

Published Online: 30 May 2015

DOI: http://dx.doi.org/10.1016/S0140-6736(15)60898-4

____________________________________________________________________________________________________________________

The Lancet

Inhibition of BRAF and MEK in BRAF-mutant melanoma

Keiran S M Smalley, Vernon K Sondak

Published Online: 30 May 2015

DOI: http://dx.doi.org/10.1016/S0140-6736(15)60972-2

_______________________________________________________________________________________________________________________________________

Cell Reports

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation

Hyungsoo Kim
Dennie T. Frederick
Mitchell P. Levesque
Zachary A. Cooper
Yongmei Feng
Clemens Krepler
Laurence Brill
Yardena Samuels
Nicholas K. Hayward
Ally Perlina
Adriano Piris
Tongwu Zhang
Ruth Halaban
Meenhard M. Herlyn
Kevin M. Brown
Jennifer A. Wargo
Reinhard Dummer
Keith T. Flaherty
Ze’ev A. Ronai